Swine Flu H1N1 Vaccine Singapore Clinic

Swine Flu H1N1 Vaccine Singapore Clinic: Swine flu / Pandemic (H1N1) 2009 vaccine jab/shot/injection clinic, Singapore. For vaccination against Swine Flu, Influenza A (H1N1), Pandemic (H1N1) 2009 - Definitions, references and latest news.

Description

We do not stock Pandemic (H1N1) 2009 Vaccine.

References

• Swine flu H1N1 vaccine - Wikipedia, the free encyclopedia
• Swine flu H1N1 vaccine: Definition from Answers.com
• Swine flu H1N1 vaccine - definition of Swine flu H1N1 vaccine in the Medical dictionary - by the Free Online Medical Dictionary, Thesaurus and Encyclopedia.
• WHO | Vaccines for pandemic influenza A (H1N1)
• CDC H1N1 Flu | H1N1 Flu Vaccination Resources
• Panvax H1N1 Vaccine and Panvax H1N1 Vaccine Junior (8 December 2009)
• MEDICATION GUIDE FOR THE PANDEMIC (H1N1) 2009 INFLUENZA VACCINE ( Chinese / Malay )

South Africa: High Risk Patients Urged to Get H1N1 Jabs
Wed, 28 Jul 2010 13:35:50 +0100 | AllAfrica News: Health and Medicine
The Gauteng Department of Health and Social Development has urged high-risk patients to visit their nearest public health facility to get vaccinated against the H1N1 influenza. (Source: AllAfrica News: Health and Medicine)

South Africa: Gauteng Citizens Urged to Vaccinate Against H1N1
Wed, 28 Jul 2010 12:23:56 +0100 | AllAfrica News: Health and Medicine
Gauteng Department of Health and Social development is urging pregnant women, patients with chronic lung and heart diseases, diabetic, school going learners under the age of 20 as well as senior citizens over 65 years to immunize against H1N1 virus by Friday, 31 July 2010. (Source: AllAfrica News: Health and Medicine)

Sustained viral load and late death in Rag2-/- mice after influenza A virus infection
Tue, 27 Jul 2010 23:00:00 +0100 | Virology Journal
The importance of the adaptive immune response for secondary influenza infections and protection from a lethal challenge after vaccination has been well documented. However, some controversy still exists concerning the specific involvement of B and T cells during a primary infection. Here, we have followed the survival, weight loss, viral load and lung pathology in Rag2-/- knock-out mice after infection with influenza A virus (H1N1). Infected wild type mice initially lost weight early after infection but then cleared the virus and recovered. Rag2-/- mice, however, showed similar weight loss kinetics in the early stages after infection but weight loss continued post infection and culminated in death. In contrast to wild type mice, Rag2-/- mice were not able to clear the virus, despite an in...

Gambia: H1N1 Pandemic Vaccination Campaign Begins
Tue, 27 Jul 2010 15:14:46 +0100 | AllAfrica News: Health and Medicine
The Ministry of Health and Social Welfare in collaboration with the World Health Organisation (WHO) yesterday started its nationwide vaccination campaign of Influenza A (H1N1) which is expected to last till 30th of July. (Source: AllAfrica News: Health and Medicine)

NHS HTA - themed issue on pandemic flu
Sun, 25 Jul 2010 23:00:00 +0100 | NeLM - Disease Focused Reviews
Source: Health Technology Assessment Area: Evidence > Disease Focused Reviews A NHS HTA report discusses a number of issues on the management of pandemic flu based on assessment of the recent H1N1 ('swine flu') pandemic. Issues examined are: . needs, concerns and behaviours of people with existing respiratory conditions . influenza A/H1N1v in pregnancy . the impact of communications about swine flu on public responses to the outbreak . the impact of illness and of school closure on social contact patterns . vaccine effectiveness; and . a Cochrane review of physical  interventions to to interrupt or reduce the spread of respiratory viruses.   The full text of the report is available online. (Source: NeLM - Disease Focused Reviews)

NEW: QUESTIONS & ANSWERS - About the Central Vaccine Recovery Program
Fri, 23 Jul 2010 16:36:05 +0100 | CDC Swine Flu Updates
This Q&A document provides information for providers who signed a Provider Agreement to administer 2009 H1N1 about the Central Vaccine Recovery Program regarding the recovery of unused and expired 2009 H1N1 vaccine. (Source: CDC Swine Flu Updates)

Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein
Fri, 23 Jul 2010 11:06:30 +0100 | Archives of Virology
In this study, the recombinant nucleoprotein (rNP) of the A/PR/8/34 (H1N1) influenza virus strain was effectively expressed using a prokaryotic expression system and then purified with a nickel-charged Sepharose affinity column as a candidate component for an influenza vaccine. The rNP was administered intranasally three times at 3-week intervals to female BALB/c mice in combination with an adjuvant (cholera toxin B subunit containing 0.2% of the whole toxin). Twenty-one days after the last immunization, the mice were challenged with homologous or heterologous influenza viruses at a lethal dose. The results showed that intranasal immunization of 10 μg rNP with adjuvant completely protected the immunized mice against the homologous influenza virus, and immunization with 100 ...

Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
Thu, 22 Jul 2010 23:00:00 +0100 | Vaccine
Authors: Girard MP, Katz J, Pervikov Y, Palkonyay L, Kieny MP On February 17-18, 2010, the World Health Organization (WHO) convened the 6th meeting on the "Evaluation of pandemic influenza vaccines in clinical trials" to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number of vaccine types were reviewed, including classical egg-derived and cell culture-derived inactivated vaccines, such as split virus or whole-virion vaccines, and live-attenuated vaccines (LAIV), as well as vaccines developed using new technologies. The amount of antigen needed, the effect of adjuvants and the number of doses required to induce adequate antibody responses in various populations, together with the issue of safety of the vacc...

Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly.
Thu, 22 Jul 2010 23:00:00 +0100 | Vaccine
This study indicated that one dose of 15mug hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively). PMID: 20659517 [PubMed - as supplied by publisher] (Source: Vaccine)